Abstract 5924
Background
Due to their advanced age many cancer patients with unfavorable prognosis suffer from comorbidities, and thus the risk of consuming potentially inappropriate medication (PIM). It is vital to deprescribe drugs with potential harmful effects or no short-term benefit for lowering pill.
Hence, we examined the degree of deprescription of potentially inappropriate medication (PIM) in patients suffering from cancer.
Methods
Retrospective, register-based study of all patients with newly diagnosed breast, prostate, pancreatic, and lung cancer, diagnosed at a hospital in the Capital Region of Denmark (1.8 million inhabitants) from 2012-2014. Patients with insufficient staging information or other malignancy except non-melanoma skin-cancer were excluded. Information about medication, comorbidity and mortality was extracted from the electronic health records.
PIM were defined as: acetylsalicylic acid, calcium channel blockers, statins, thiazides, and bisphosphonates. The study was approved by the Danish Patient Safety Authority (No. 3-3013-1884/1/) and the Danish Data Protection Agency (No. BFH-2016-058).
Results
Table:
1607P
Breast (n = 3,959)/prostate cancer (n = 3,535) (total n = 7,494) | Lung (n = 2,824)/pancreatic cancer (n = 617) (n = 3,441) | |
---|---|---|
Gender (Women) | 52% | 50% |
Age mean (sd) | 65 (12) | 70 (10) |
1-year Survival | 97% | 46% |
Metastatic disease | 6.7% | 52% |
Co-morbidities | ||
Diabetes | 4.0 % | 9.7 % |
Hypertension | 12 % | 23 % |
Atrial fibrillation | 4.7 % | 8.7 % |
Ischemic heart disease | 6.4 % | 11.6 % |
Heart failure | 2.2 % | 5.6 % |
Ischemic stroke | 1.5 % | 2.8 % |
Medication | 1-year deprescription/total treated§ | |
Acetylsalicylic acid | 250/1,443 (17%) | 398/928 (43%) |
Calcium channel blockers | 135/1,048 (13%) | 284/659 (43%) |
Statins | 187/1,769 (11%) | 501/1,066 (47%) |
Thiazide diuretics | 175/954 (18%) | 259/534 (49%) |
Bisphosphonates | 26/319 (8.2%) | 64/171 (37%) |
Deprescribed during the first year after cancer-diagnosis/total number of patients treated
(Patients not surviving 1 year and treatment continuing until death does not count towards deprescribed)
Conclusions
Our findings show that oncologists and physicians have a rational approach to deprescription in patients suffering from cancer with short-term (pancreatic and lung cancer) respectively long-term (breast and prostate cancer) survival rates. However, several patients were continuing potential inappropriate medications in the terminal stage of cancer.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
592 - Effects of novel targeted anticancer drugs on cytotoxicity, apoptosis, angiogenesis, EMT, drug resistance and autophagic mechanism
Presenter: Seyma Aydinlik
Session: Poster Display session 1
Resources:
Abstract
3235 - Delineating the mechanisms of alpha 1-3 fucosyltransferase FUT11 in ovarian cancer
Presenter: Qi Chen
Session: Poster Display session 1
Resources:
Abstract
3577 - The tyrosine kinase inhibitor Dasatinib blocks tumor growth, invasion and recurrence potential by interrupting the communication between cancer cells and their surrounding microenvironment in triple negative breast cancer
Presenter: Miriam Nuncia-Cantarero
Session: Poster Display session 1
Resources:
Abstract
4808 - NORE1A induces a feedback termination of TNF signaling by antagonizing TNFR1 through ITCH-mediated destruction complex
Presenter: Jieun Ahn
Session: Poster Display session 1
Resources:
Abstract
1294 - Hsp90 inhibitors enhance the antitumoral effect of osimertinib and overcome osimertinib resistance in non-small-cell cell lung cancer cell models
Presenter: Jordi Codony-Servat
Session: Poster Display session 1
Resources:
Abstract
1559 - Expression of IL-17RA promotes cancer stem-like properties of colorectal cancer cells by Stat3 activation
Presenter: Chih-Yung Yang
Session: Poster Display session 1
Resources:
Abstract
1615 - Adaption of Pancreatic Cancer Cells to AKT1 Inhibition Induces the Acquisition of Cancer Stem-Cell Like Phenotype Through Upregulation of Mitochondrial Functions
Presenter: Hugo Arasanz
Session: Poster Display session 1
Resources:
Abstract
4793 - Bub3 is phosphorylated by the Ataxia-Telangiectasia Mutated Kinase in mitosis and required for activation of the mitotic spindle checkpoint in Breast Cancer
Presenter: Mingming Xiao
Session: Poster Display session 1
Resources:
Abstract
1448 - The regulation of INK4 locus by long non-coding RNAs
Presenter: Yojiro Kotake
Session: Poster Display session 1
Resources:
Abstract
1858 - Vascular Endothelial Growth Factor in Colorectal Cancer Pathology, Survival and Treatment
Presenter: Liz Baker
Session: Poster Display session 1
Resources:
Abstract